Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
7
sulfamethoxazole for the
treatment of Pneumocystis
jirovecii pneumonia (PCP) and
toxoplasmosis have not been
studied and should be avoided.
ANTIFUNGALS
Fluconazole/Lamivudine Interaction not studied. As only limited data are
Fluconazole/Zidovudine Zidovudine AUC 74% available the clinical
(400 mg once daily/200 mg significance is not known.
thrice daily) (UGT inhibition) Monitor for signs of
zidovudine toxicity (see
section 4.8).
ANTIMYCOBACTERIALS
Rifampicin/Lamivudine Interaction not studied. Insufficient data to
Rifampicin/Zidovudine (600 Zidovudine AUC 48% recommend dosage
mg once daily/200 mg thrice adjustment.
daily) (UGT induction)
ANTICONVULSANTS
Phenobarbital/Lamivudine Interaction not studied. Insufficient data to
Phenobarbital/Zidovudine Interaction not studied. recommend dosage
adjustment.
Potential to slightly decrease
zidovudine plasma
concentrations through UGT
induction.
Phenytoin/Lamivudine Interaction not studied. Monitor phenytoin
Phenytoin/Zidovudine Phenytoin AUC concentrations.
Valproic acid/Lamivudine Interaction not studied. As only limited data are
Valproic acid/Zidovudine Zidovudine AUC 80% available the clinical
(250 mg or 500 mg thrice significance is not known.
daily/100 mg thrice daily)
(UGT inhibition) Monitor for signs of
zidovudine toxicity (see
section 4.8).
ANTIHISTAMINES (HISTAMINE H1 RECEPTOR ANTAGONISTS)
Ranitidine/Lamivudine Interaction not studied. No dosage adjustment
necessary.
Clinically significant
interaction unlikely. Ranitidine
eliminated only in part by renal
organic cation transport system.
Ranitidine/Zidovudine Interaction not studied
Cimetidine/Lamivudine Interaction not studied. No dosage adjustment
necessary.
Clinically significant
interaction unlikely.
Cimetidine eliminated only in
part by renal organic cation
transport system.
Cimetidine/Zidovudine Interaction not studied.
CYTOTOXICS
Cladribine/Lamivudine Interaction not studied Therefore the concomitant use
of lamivudine with cladribine
In vitro lamivudine inhibits the is not recommended
intracellular phosphorylation of (see section 4.4)
cladribine leading to a potential
risk of cladribine loss of
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
8
efficacy in case of combination
in the clinical setting. Some
clinical findings also support a
possible interaction between
lamivudine and cladribine
OPIOIDS
Methadone/Lamivudine Interaction not studied. As only limited data are
Methadone/Zidovudine Zidovudine AUC 43% available the clinical
(30 to 90 mg once daily/200 mg Methadone AUC significance is not known.
every 4 hours) Monitor for signs of
zidovudine toxicity (see
section 4.8).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
10
Drugs by Therapeutic Interaction Recommendation
Area Geometric mean change concerning co-
(%) administration
(Possible mechanism)
CYTOTOXICS
Cladribine/Lamivudine Interaction not studied. Therefore, the concomitant
use of lamivudine with
In vitro lamivudine inhibits the cladribine is not
intracellular phosphorylation of recommended (see section
cladribine leading to a potential 4.4).
risk of cladribine loss of efficacy
in case of combination in the
clinical setting. Some clinical
findings also support a possible
interaction between lamivudine
and cladribine.
OPIOIDS
Methadone/Abacavir Abacavir: AUC As only limited data are
(40 to 90 mg once daily for 14 Cmax 35% available the clinical
days/600 mg single dose, then significance is not known.
600 mg twice daily for 14 Methadone: CL/F 22% Monitor for signs of
days) zidovudine toxicity (see
Methadone/Lamivudine Interaction not studied. section 4.8).
Methadone/Zidovudine Zidovudine AUC 43%
(30 to 90 mg once Methadone AUC Methadone dosage adjustment
daily/200 mg every 4 hours) unlikely in majority of
patients; occasionally
methadone re-titration may be
required.
RETINOIDS
Retinoid compounds Interaction not studied. Insufficient data to
(e.g. isotretinoin)/Abacavir recommend dosage
Possible interaction given adjustment.
common pathway of elimination
via alcohol dehydrogenase.
Retinoid compounds Interaction not studied.
(e.g. isotretinoin)/Lamivudine
No drug interaction studies
Retinoid compounds Interaction not studied.
(e.g. isotretinoin)/Zidovudine
URICOSURIC
Probenecid/Abacavir Interaction not studied. As only limited data are
Probenecid/Lamivudine Interaction not studied. available the clinical
Probenecid/Zidovudine Zidovudine AUC 106% significance is not known.
(500 mg four times Monitor for signs of
daily/2 mg/kg thrice daily) (UGT inhibition) zidovudine toxicity (see
section 4.8).
MISCELLANEOUS
Ethanol/Abacavir Abacavir: AUC 41% No dosage adjustment
(0.7 g/kg single dose/600 mg Ethanol: AUC necessary.
single dose)
(Inhibition of alcohol
dehydrogenase)
Ethanol/Lamivudine Interaction not studied.
Ethanol/Zidovudine Interaction not studied.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2026-01-19T14:10:00Z · SHA-256 0fa44d429f9cace08dce2fd9d8c4f2ed838fc8cb0ed1b7cfc79bd6b9caa26349 · Passage 779b308db2f1cd8ed7b6c3456196c746580180c3977235a9bdd446b4f2a52234 · Zeichen 9177–13020 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.